{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:18Z","timestamp":1792800858656,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aggressive chemoradiotherapy for limited-stage small cell lung cancer (SCLC) frequently causes severe hematologic toxicities, particularly chemotherapy-induced thrombocytopenia (CIT), which can compromise treatment efficacy. While thrombopoietin receptor agonists (TPO-RAs) are preferred for CIT management, refractory cases pose significant challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A patient with stage IIIC (cT3N3M0) limited-stage SCLC achieved a durable partial response exceeding five years following etoposide\/cisplatin chemotherapy and concurrent thoracic radiotherapy (60 Gy). However, severe, persistent, and refractory CIT developed, unresponsive to multiple interventions including recombinant human thrombopoietin (rhTPO), avatrombopag, eltrombopag, corticosteroids, thalidomide, tretinoin, and intermittent platelet transfusions. Bone marrow aspiration confirmed profound hypocellularity and megakaryocytic hypoplasia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention &amp;amp; outcome<\/jats:title>\n                    <jats:p>Initiation of subcutaneous romiplostim successfully elevated and maintained platelet counts, enabling sustained disease control. Platelet counts declined rapidly below 100\u00d710&amp;amp;xxx2079;\/L upon extending the dosing interval beyond 3-4 weeks, indicating that platelet maintenance remained dependent on continued romiplostim administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates romiplostim\u2019s efficacy in managing severe, refractory CIT following intensive SCLC therapy, facilitating long-term disease control in a sustained responder. It highlights the critical role of TPO-RAs in this setting but underscores challenges including ongoing dependence on continued romiplostim for platelet maintenance and the need for strategies to coordinate romiplostim with future systemic therapies should disease progression occur. The potential for loss of romiplostim response necessitates exploration of alternative approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1854366","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:30:07Z","timestamp":1789619407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Romiplostim for refractory chemotherapy-induced thrombocytopenia in a long-term survivor of limited-stage small cell lung cancer: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Mingfang","family":"Wang","sequence":"first","affiliation":[{"name":"Yidu Central Hospital of Weifang","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tian","sequence":"additional","affiliation":[{"name":"Yidu Central Hospital of Weifang","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taosheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Yidu Central Hospital of Weifang","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[{"name":"Yidu Central Hospital of Weifang","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Yidu Central Hospital of Weifang","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Yidu Central Hospital of Weifang","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155810","article-title":"Unraveling the pathogenesis of myelosuppression and therapeutic potential of natural products","volume":"132","author":"Nian","year":"2024","journal-title":"Phytomedicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1290-x","article-title":"Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy","volume":"20","author":"Wu","year":"2012","journal-title":"Support Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-880","article-title":"Cost-effectiveness analysis of rhTPO and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in hematological tumors based on real-world data","volume":"11","author":"Zhang","year":"2022","journal-title":"Ann Palliat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: A review in thrombocytopenia","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P042","article-title":"Eltrombopag: A novel oral thrombopoietin receptor agonist","volume":"44","author":"Corman","year":"2010","journal-title":"Ann Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2023.05.008","article-title":"Advancements in small cell lung cancer","volume":"93","author":"Lee","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","article-title":"Emerging strategies for the treatment of small cell lung cancer: A review","volume":"9","author":"Petty","year":"2023","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01639","article-title":"Radiation and systemic therapy for limited-stage small-cell lung cancer","volume":"40","author":"Bogart","year":"2022","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101257","article-title":"Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review","volume":"70","author":"Mei","year":"2025","journal-title":"Blood Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): An open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2020570","article-title":"Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: A retrospective analysis of electronic medical data from community cancer care providers","volume":"25","author":"Epstein","year":"2022","journal-title":"J Med Econ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/10428190600909115","article-title":"The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes","volume":"48","author":"Bhatia","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-1023","article-title":"Host IL11 signaling suppresses CD4+ T cell\u2013mediated antitumor responses to colon cancer in mice","volume":"9","author":"Huynh","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12967-023-04079-6","article-title":"Pharmacologic inhibition of IL11\/STAT3 signaling increases MHC-I expression and T cell infiltration","volume":"21","author":"Xiong","year":"2023","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319200","article-title":"STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis","volume":"69","author":"Heichler","year":"2020","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2201428","article-title":"Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2022.2157806","article-title":"Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory\/relapsed primary immune thrombocytopenia: A multicenter, randomized controlled trial and pharmacokinetics study","volume":"34","author":"Liu","year":"2023","journal-title":"Platelets"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28041953","article-title":"rhTPO ameliorates radiation-induced long-term hematopoietic stem cell injury in mice","volume":"28","author":"Luan","year":"2023","journal-title":"Molecules"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy\u2010induced thrombocytopenia: Modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy\u2010induced thrombocytopenia: A review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19074","article-title":"Immunomodulation with romiplostim as a second\u2010line strategy in primary immune thrombocytopenia: The iROM study","volume":"203","author":"Schifferli","year":"2023","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511882","article-title":"Romiplostim versus placebo for chemotherapy-induced thrombocytopenia","volume":"394","author":"Al-Samkari","year":"2026","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1549214","article-title":"Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: A systematic review and network meta-analysis","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12885-026-15678-z","article-title":"Comparison of the real-world efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in chemotherapy-induced thrombocytopenia","volume":"26","author":"Cheng","year":"2026","journal-title":"BMC Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0950-6","article-title":"High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag","volume":"35","author":"Hosokawa","year":"2021","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2514791","article-title":"Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: A single-center retrospective study","volume":"57","author":"Lin","year":"2025","journal-title":"Ann Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00240-4","article-title":"All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"8","author":"Huang","year":"2021","journal-title":"Lancet Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1854366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:30:12Z","timestamp":1789619412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1854366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1854366"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1854366","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1854366"}}